- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00323115
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
A Phase II Feasibility Study of Adjuvant Intra-Nodal Autologous Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven GBM with central pathology review at Dartmouth-Hitchcock Medical Center (DHMC)
- Tumor specimen obtained at the time of surgery adequate for vaccination
- 18 years of age or older
- Karnofsky Performance Status 60% or greater
- Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10 9th/L
- Platelets greater than or equal to 100 x 10 9th/L
- Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) less than or equal to 5 times the upper limits of normal (ULN)
- Total bilirubin less than or equal to 1.5 times ULN
- Serum creatinine less than or equal to 1.5 times ULN, OR estimated creatinine clearance greater than or equal to 60 mL/min
- No known immunosuppression other than chemo-related
- Negative HIV serologies
- No evidence of acute or chronic hepatitis on standard hepatitis C and B screening tests
- No chemotherapy within four weeks prior to leukapheresis
- Radiotherapy at outside institution is permitted if tissue was obtained at time of surgery at DHMC and patient is willing to follow-up per protocol
- Off steroids for at least two weeks before leukapheresis
- No second malignancies except non-melanoma skin cancer, and non-invasive cancer such at cervical CIS, superficial bladder cancer or breast CIS
- Negative serum or urine pregnancy test for women of childbearing potential
- No serious uncontrolled medical disorder or active infection
- All patients must give informed consent
- No history of clinical evidence of active autoimmune disease
Exclusion Criteria:
- Invasive cancers in the past 5 years
- Rheumatologic/autoimmune disease
- Pregnancy or unwillingness to remain on acceptable form of birth control during study
- Major cardiac, pulmonary, or other systemic disease; viral hepatitis; HIV infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Vaccine
|
Vaccine given by cervical lymph node injection 3 times every other week
Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
RT is standard of care (SOC) post surgery
Vaccine given cervical lymphnode injection 3 times every other week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor-specific Cytotoxic T-cell Response
Time Frame: Day 42
|
MRI & pheresis post vaccine
|
Day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events: Toxicity Profile of Intra-nodal DC/Tumor Lysate Vaccination
Time Frame: Until death or approximately 24 months after diagnosis
|
Adverse events attributed to vaccination.
Collected and attributed adverse events at each study visit; monitored participants for adverse events for two hours following vaccination procedure.
|
Until death or approximately 24 months after diagnosis
|
Number of Participants With Evaluable Data: Feasibility of Vaccination
Time Frame: Through enrollment, approximately 2 years
|
To determine the feasibility of this approach, the investigators hypothesize that at least 2/3 of the patients included in the study will be evaluable, meaning that the participants would have received the 3 vaccinations with immunologic outcome parameters measured before and after vaccination.
Therefore a maximum of 15 patients would be enrolled in the study to obtain 10 evaluable patients.
If after enrolling 15 patients the investigators are unable to obtain 10 evaluable patients, the investigators would consider this approach not feasible.
|
Through enrollment, approximately 2 years
|
Progression Free Survival (PFS)
Time Frame: Approximately 42 months
|
Progression-free survival will be assessed for each patient as the time from surgery until the patient reaches objective disease progression by MRI criteria.
Death will be regarded as a progression event in those patients that die before disease progression.
Patients without documented objective progression at the time of the analysis will be censored at the date of their last objective tumor assessment.
Since disease free survival and overall survival are secondary endpoints all patients will be followed until death or for a period of 5 years following enrollment.
|
Approximately 42 months
|
Number of Participants With Significant Difference in Tumor Volume Size Pre- and Postvaccination: Neuroimaging and Tumor Assessment
Time Frame: baseline and 4 weeks
|
Patients with evidence of evaluable enhancing disease on contrast-enhanced MRI performed within four weeks of study entry will be evaluated for response rate.
Patients will be evaluated for objective tumor assessments by gadolinium-enhanced magnetic resonance imaging (Gd-MRI).
Comparisons of objective assessments, excluding progressive disease, are based upon major changes in tumor size on the Gd-MRI compared to the baseline scan.
Determination of progressive disease is based upon comparison to the previous scan with volumetric analysis.
|
baseline and 4 weeks
|
Overall Survival Duration: Efficacy Parameters
Time Frame: Approximately 42 months
|
Overall survival will also be followed.
Survival will be assessed from the date of surgery to the date of patient death, due to any cause, or to the last date the patient was known to be alive.
|
Approximately 42 months
|
Frequency of CD4+ and CD8+ T Cells - the Proportion of Cells in the Parent Population Responding to Glioblastoma Multiforme (GBM) - Median
Time Frame: Day 7 (pre-vaccination) and Day 42 (post-vaccination).
|
Pre- and post-vaccine immune assay results (Tumor-specific T-cells ) are summarized on a continuous scale as median.
|
Day 7 (pre-vaccination) and Day 42 (post-vaccination).
|
Percentage of Tumor-specific T-cells - Correlation Between Immunological Parameters and Efficacy- Median
Time Frame: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Pre- and post-vaccine immune assay results (Tumor-specific T-cell Responses) are summarized on a continuous scale as median.
|
Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Number of Enzyme-linked Immunosorbent Spots (ELISPOT) - Correlation Between Immunological Parameters and Efficacy - Median
Time Frame: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Pre- and post-vaccine immune assay results (Tumor-specific T-cell Responses) are summarized on a continuous scale as mean.
|
Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Frequency of CD4+ and CD8+ T Cells - the Proportion of Cells in the Parent Population Responding to Glioblastoma Multiforme (GBM) - Mean
Time Frame: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Pre- and post-vaccine immune assay results (Tumor-specific T-cells ) are summarized on a continuous scale as mean.
|
Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Percentage of Tumor-specific T-cells - Correlation Between Immunological Parameters and Efficacy- Mean
Time Frame: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Pre- and post-vaccine immune assay results (Tumor-specific T-cell Responses) are summarized on a continuous scale as median.
IFN = interferon.
|
Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Number of Enzyme-linked Immunosorbent Spots (ELISPOT) - Correlation Between Immunological Parameters and Efficacy - Mean
Time Frame: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Pre- and post-vaccine immune assay results (Tumor-specific T-cell Responses) are summarized on a continuous scale as mean.
|
Day 7 (pre-vaccination) and Day 42 (post-vaccination)
|
Evaluation of T Cell Characteristics
Time Frame: Before starting radiation/Temozolomide and at Day 7 and Day 42.
|
Peripheral blood obtained before starting radiation/ temozolomide (TMZ), and at first and second leukapheresis will be used to do lymphocyte phenotyping.
We will determine percentages of CD3+/CD8+/CD45RO+ (memory T-cells), CD3+/CD8+/CD28- (CD8 suppressor T cell phenotype), and CD4+/CD25+ cells at those 3 time points.
An anti-human Foxp3 antibody will be used to determine if the CD4+/CD25+ cells are T regulatory cells (TREG) and how the compartmental shift correlates with immunoresponse by other immune parameters as well as to efficacy.
|
Before starting radiation/Temozolomide and at Day 7 and Day 42.
|
Immunohistochemistry
Time Frame: Approximately 42 months
|
Pathologic specimen obtained from patients who require of another surgical resection after vaccination will be examined to determine the characteristics of infiltrating tumor cells. Paraffin sections of tumor specimen will be stained by immunohistochemistry with antibodies to identify the components of the inflammatory response. This specimen will be compared to the one obtained at the time of initial surgery and changes in inflammation and inflammatory cellular components will be noted. |
Approximately 42 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Camilo E. Fadul, MD, Dartmouth-Hitchcock Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
Other Study ID Numbers
- D0536
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
TVAX BiomedicalFDA Office of Orphan Products DevelopmentRecruitingGlioblastoma Multiforme of BrainUnited States
-
Shenzhen Geno-Immune Medical InstituteEnrolling by invitationGlioblastoma Multiforme | Glioblastoma Multiforme of BrainChina
-
University of Roma La SapienzaCompletedGlioblastoma Multiforme of Brain
-
University of UtahWithdrawnGlioblastoma Multiforme (GBM)United States
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Sunnybrook Health Sciences CentreRecruitingGlioblastoma Multiforme, AdultCanada
Clinical Trials on Autologous Dendritic Cell
-
University Hospital, AntwerpCompletedRenal Cell Carcinoma | Glioblastoma | Malignant Mesothelioma | Colorectal Tumors | Breast Cancers | SarcomasBelgium
-
Jan WalewskiCompletedLymphoma | Multiple Myeloma and Plasma Cell NeoplasmPoland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Immunex CorporationWithdrawnAcute Myelogenous Leukemia | Chronic Myelogenous Leukemia
-
Rockefeller UniversityMemorial Sloan Kettering Cancer CenterCompleted
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)UnknownMelanoma (Skin)United States
-
Stanford UniversityNational Institutes of Health (NIH)TerminatedLiver CancerUnited States
-
Clinica Universidad de Navarra, Universidad de...National Institutes of Health (NIH); Spanish Clinical Research Network - SCReNCompletedStage II Breast Cancer | Stage III Breast CancerSpain
-
University of PittsburghCompletedSezary Syndrome | Cutaneous T-cell LymphomaUnited States
-
Maria Sklodowska-Curie National Research Institute...Unknown
-
Chang Gung Memorial HospitalNot yet recruiting